journal article·2019-12-04Open access

MiR-30a-5p frequently downregulated in prostate cancer inhibits cell proliferation via targeting PCLAF

Hu Zhao, Wei Zhang, Xiaofeng Lai, Hehuan Zhu, Shenhang Zhang, Weizhen Wu, Shuiliang Wang, Minying Tang, Zhen Deng, Jianming Tan

Abstract

MicroRNAs (miRNAs) have vastly expanded our view of RNA world in intracellular signal regulating networks. Here, we functionally characterized a normally highly expressed miRNA, miR-30a-5p (MIMAT0000087), which exhibits downregulated expression profiles in prostate cancer samples. MiR-30a-5p knockdown and overexpression in PC-3 cell line alters cell proliferation supporting a tumour suppressor role. We also discovered that PCLAF is the direct target of miR-30a-5p. Notably, PC-3 cell proliferation is inhibited by miR-30a-5p/PCLAF axis. miR-30a-5p represents a novel molecule of functionally important miRNAs which may shed light on the novel therapeutic targets for prostate cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: MicroRNA in disease regulation · RNA Research and Splicing · Circular RNAs in diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Fujian Provincial Key Laboratory of Transplant Biology, Fuzhou Dongfang Hospital of Xiamen University (900 Hospital of the Joint Logistics Team)

Fujian Provincial Key Laboratory of Transplant Biology, 900 Hospital of the Joint Logistics Team, Fujian Medical University

Department of Urology, Bayi Hospital affiliated Nanjing University of Chinese Medicine

Department of Clinical Genetics and Experimental Medicine, 900 Hospital of the Joint Logistics Team, Xiamen University School of Medicine

ChinaFujian Key Laboratory of Exercise Rehabilitation, College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine

Funding

Military Medical Scientific Youth Cultivation · Outstanding Youth Funds of Fuzhou General Hospital

References (40)

Show source-provided references
1. 10.3322/caac.2133210.3322/caac.21332 ↗
2. 10.1016/j.semradonc.2016.08.00210.1016/j.semradonc.2016.08.002 ↗
3. 10.1016/S0140-6736(14)60525-010.1016/S0140-6736(14)60525-0 ↗
4. 10.1016/j.eururo.2014.10.02110.1016/j.eururo.2014.10.021 ↗
5. 10.4103/1008-682X.13278010.4103/1008-682X.132780 ↗
6. 10.1016/j.tcb.2014.11.00410.1016/j.tcb.2014.11.004 ↗
7. 10.1007/978-1-4939-7046-9_1210.1007/978-1-4939-7046-9_12 ↗
8. 10.1002/pros.2293610.1002/pros.22936 ↗
9. 10.1177/101042831769220410.1177/1010428317692204 ↗
10. 10.1038/s41598-017-16175-x10.1038/s41598-017-16175-x ↗
11. 10.1038/onc.2013.20010.1038/onc.2013.200 ↗
12. 10.18632/oncotarget.1879510.18632/oncotarget.18795 ↗
13. 10.1038/mt.2016.10910.1038/mt.2016.109 ↗
14. 10.7908/C10R9NV410.7908/C10R9NV4 ↗
15. 10.1093/nar/gkw107910.1093/nar/gkw1079 ↗
16. 10.1093/nar/gkv40310.1093/nar/gkv403 ↗
17. 10.1093/nar/gkw11610.1093/nar/gkw116 ↗
18. 10.1093/nar/gkm101210.1093/nar/gkm1012 ↗
19. 10.1093/nar/gkx109010.1093/nar/gkx1090 ↗
20. 10.1093/nar/gkx106710.1093/nar/gkx1067 ↗
21. 10.7554/eLife.0500510.7554/eLife.05005 ↗
22. 10.1016/j.neo.2017.05.00210.1016/j.neo.2017.05.002 ↗
23. 10.1038/nature1100310.1038/nature11003 ↗
24. 10.1093/nar/gkx85110.1093/nar/gkx851 ↗
25. 10.1186/1471-2164-14-13910.1186/1471-2164-14-139 ↗
26. 10.1158/0008-5472.CAN-13-3311-T10.1158/0008-5472.CAN-13-3311-T ↗
27. Fan MJ, Zhong YH, Shen W, et al. MiR-30 suppresses lung cancer cell 95D epithelial mesenchymal transition and invasion through targeted regulating Snail. Eur Rev Med Pharma Sci. 2017;21:2642–2649.
28. 10.3892/mmr.2014.249410.3892/mmr.2014.2494 ↗
29. Xu CG, Yang MF, Fan JX, et al. MiR-30a and miR-205 are downregulated in hypoxia and modulate radiosensitivity of prostate cancer cells by inhibiting autophagy via TP53INP1. Eur Rev Med Pharma Sci. 2016;20:1501–1508.
30. 10.18632/oncotarget.69610.18632/oncotarget.696 ↗
31. 10.18632/oncotarget.1224110.18632/oncotarget.12241 ↗
32. 10.1186/s12920-017-0300-310.1186/s12920-017-0300-3 ↗
33. 10.1080/21691401.2016.119645610.1080/21691401.2016.1196456 ↗
34. 10.1111/cas.1208310.1111/cas.12083 ↗
35. 10.1038/labinvest.2013.12410.1038/labinvest.2013.124 ↗
36. 10.1371/journal.pone.002686610.1371/journal.pone.0026866 ↗
37. 10.1007/s13277-013-1353-310.1007/s13277-013-1353-3 ↗
38. 10.1158/0008-5472.CAN-06-435610.1158/0008-5472.CAN-06-4356 ↗
39. 10.1016/j.lungcan.2011.05.02410.1016/j.lungcan.2011.05.024 ↗
40. 10.1016/j.eururo.2015.10.04210.1016/j.eururo.2015.10.042 ↗